US Stock Movement: Caris Life Sciences slumps on November 16 – Q3 net profit declines, operating expense guidance raised, negative free cash flow
Bitget异动解读2026/11/16 15:31Caris Life Sciences November 16 Plunge Interpretation
Keywords: Q3 net profit decline, operating expense guidance raised, negative free cash flow
1. Caris Life Sciences announced its third quarter 2026 results after the market closed on November 4. Earnings per share were $0.05, down 37.5% from $0.08 in the same period last year. Net profit decreased from $24.3 million a year earlier to $15.3 million, indicating a year-on-year drop in profitability.
2. The company raised its full-year 2026 operating expense guidance to approximately $620 million, driven by an expanded sales team growing to 325 people and increased investment in new testing products, with rising expenses further suppressing profit expectations.
3. Free cash flow for the third quarter was negative $39.7 million, with net cash used in operating activities totaling $22.2 million. The cash burn has raised concerns about the company's short-term financial health.
(Disclaimer: This content is generated by AI technology, which summarizes publicly available information. It is for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
OpenAI expands AMD computing power layout: signs six-year agreement with TensorWave to deploy over 450MW of computing power
TensorWave will provide OpenAI with 457MW of IT computing capacity in the US for a period of six years, fully equipped with AMD Instinct MI455X GPUs, with operations expected to begin in the first half of 2027. TensorWave, supported by AMD Ventures, completed a Series B round of financing in June this year, aiming to accelerate the deployment of AMD computing power.
